Abstract
Drug acquisition costs are a key driver of cost-effectiveness of chemotherapy treatments. Costs are proportionate to the dose required, often calculated based on weight or body-surface-area (BSA). Combined with dose banding and wastage, these factors introduce uncertainty around the true cost of drug acquisition. This study aimed to estimate mean treatment costs using a range of methods identified from published NICE appraisals, and to assess the sensitivity of estimated costs to the method used.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
